deltatrials
Completed OBSERVATIONAL NCT04749810

Observational Study of Elizaria® in aHUS Patients

Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria® in Patients With Atypical Hemolytic Uremic Syndrome

Sponsor: AO GENERIUM

Interventions Elizaria®
Updated 5 times since 2021 Last updated: Aug 2, 2022 Started: Dec 19, 2019 Primary completion: Feb 28, 2022 Completion: Apr 30, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Atypical Hemolytic Uremic Syndrome and aHUS and is currently completed. AO GENERIUM leads this study, which shows 5 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Mar 2021 – ~Sep 2022 · 18 months · monthly snapshotRecruiting~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

5 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed

  2. Sep 2024 — Sep 2025 [monthly]

    Completed

  3. Jul 2024 — Sep 2024 [monthly]

    Completed

  4. Sep 2022 — Jul 2024 [monthly]

    Completed

    Status: RecruitingCompleted

  5. Mar 2021 — Sep 2022 [monthly]

    Recruiting

    First recorded

Dec 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AO GENERIUM
Data source: AO GENERIUM

For direct contact, visit the study record on ClinicalTrials.gov .